Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

contract pharmacal corporation - calcium, vitamin d3, magnesium, zinc, copper, manganese, boron - tablets film-coated - 500mg+ 400iu+ 40mg+ 7,5mg+ 1mg+ 1,8mg+ 250mcg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

bilim ilac sanayi ve ticaret anonim sirketi, turkey - rosuvastatin - film coated tablet - 10 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

bilim ilac sanayi ve ticaret anonim sirketi, turkey - rosuvastatin - film coated tablet - 20 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.2 mg (equivalent: lincomycin, qty 300 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.26 mg/ml (equivalent: lincomycin, qty 300 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - indications as at 22 september 1994: lincocin is indicated in the treatment of serious infections due to susceptible strains of gram positive aerobes such as streptococci, pneumococci and staphylococci. its use should be reserved for penicillin allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g.erythromycin). lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincocin have been recovered; culture and susceptibility studies should be done in conjunction with lincocin therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with

United States - English - NLM (National Library of Medicine)

praxgen pharmaceuticals llc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. the drug may be administered concomitantly with other antimicrobial agents when indicated. lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that a

United States - English - NLM (National Library of Medicine)

micro labs limited - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly susp

United States - English - NLM (National Library of Medicine)

gland pharma limited - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin injection is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - lincomycin (unii: bod072yw0f) (lincomycin - unii:bod072yw0f) - lincomycin injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin injection is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infection